JNJ-4496 CAR-T Therapy Demonstrates 100% Response Rate in First-Line Treated r/r LBCL Patients, Showing Potential Curative Benefit

2025Year6Month13Johnson & Johnson announced its dual-target blood cancerCAR-TThe first batch of clinical data for the project, for recurrent or refractory largeBBrings New Hope to Patients with Lymphoma.

 Clinical Trial Results Are Encouraging

In a1bIn the clinical trial period,22Name accepted the recommended2Periodic DoseCAR-TPatients receiving the therapy were included in the efficacy data analysis, with a median follow-up time of4Months. Among them,10Patients who had previously received only first-line treatment showed particularly outstanding results, with an objective response rate (ORR) has reached100%, which means that all patients showed remission of cancer signs. More encouragingly,8No signs of cancer were detected in the patient's body.

For12The objective response rate was observed in patients who had received two or more prior lines of therapy.92%, The complete remission rate is75%. This result indicates that, regardless of the number of prior treatment lines the patients had received,CAR-TThe therapies have demonstrated significant efficacy.

In terms of safety,25In the safety cohort of patients,84%The patients experienced3Level or4Grade-related adverse events,28%of patients experienced severe side effects. Notably, Johnson & Johnson stated that there were no3Level or4Grade Cytokine Release Syndrome (CRS) cases.1Patients appeared1Grade Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), another1A patient with central nervous system lymphoma developed3LevelICANS。

The1bThe primary endpoint of the trial is the incidence of adverse events (including dose-limiting toxicity) and the recommended2Determination of the period dose. Johnson & Johnson stated in the press release that the recommended2The dose for the period is750010,000CAR-TCells, but the press release did not mention dose-limiting toxicity.

This autologousCAR-TTherapy simultaneously targetsCD19AndCD20, Both of these are cancerous.BCell surface proteins commonly expressed by cells. Currently available monoclonal antibodies targetCD19 CAR-TTherapy, only about40%Patients can achieve long-term remission. The data released this time show encouraging clinical activity and promising safety, representing a step forward in providing potential new treatment options for patients with the most common type of aggressive lymphoma.

 Powerful Alliance, Return to the CAR-T Field

JNJ-449By Johnson & Johnson2023Year and Sino-American Biotechnology CompanyAbelZeta(Cellular Biomedicine Group) through a cooperation and licensing agreement. According to the agreement, Johnson & Johnson's pharmaceutical division, Janssen (Janssen) Paid2.45USD billion as an upfront payment, obtainedJNJ-4496(In China, referred to asC-CAR039) and another namedC-CAR066TargetedCD20TheCAR-TRights outside of mainland China.

This time withAbelZetaThe deal marks Johnson & Johnson's2022Year and Legend Biotech (Legend Biotech) CooperationCarvyktiAfter Approval, ReturnCAR-TField. While its pharmaceutical competitors such as Novartis, Gilead, and AstraZeneca were actively advancing in the field, Johnson & Johnson chose to wait until the right opportunity emerged.

However, the cell therapy field has gradually shrunk since then due to high costs and clinical challenges. Earlier this year,Carisma TherapeuticsAndVor BioCell therapy biotech companies announce closure, whileCAR-TCompanyCargo TherapeuticsIn3Monthly sales of all assets and layoffs90%. In such a large environment, the positive clinical data announced by Johnson & Johnson this time undoubtedly providesCAR-TThe field has been given a strong boost.

Johnson & Johnson in LymphomaCAR-TThis breakthrough in the treatment field not only brings new hope for patients but also provides new momentum for the development of the entire cell therapy field. With this global open-label1bAs the ongoing research continues, we are expected to see more data on the long-term efficacy and safety of this therapy, laying a stronger foundation for its future clinical applications.

Source:fierce biotech